A5065010794- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Renal and related cancers
- Genetic and Kidney Cyst Diseases
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Genomics and Chromatin Dynamics
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- COVID-19 Clinical Research Studies
- Infection Control and Ventilation
- Microtubule and mitosis dynamics
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Wildlife-Road Interactions and Conservation
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Genital Health and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Monoclonal and Polyclonal Antibodies Research
- Statistical Methods in Clinical Trials
- Ethics in Clinical Research
- Urologic and reproductive health conditions
University of North Carolina at Chapel Hill
2013-2025
UNC Lineberger Comprehensive Cancer Center
2014-2025
Vanderbilt University Medical Center
2023-2024
Vanderbilt-Ingram Cancer Center
2023
Vanderbilt University
2023
VA Tennessee Valley Healthcare System
2023
John Wiley & Sons (United States)
2018
Ecological Society of America
2018
Pediatrics and Genetics
2016
Segeberger Kliniken
2016
Loss of the short arm chromosome 3 (3p) occurs early in >95% clear cell renal carcinoma (ccRCC). Nearly ubiquitous 3p loss ccRCC suggests haploinsufficiency for tumor suppressors as drivers tumorigenesis. We previously reported methyltransferase SETD2, which trimethylates H3 histones on lysine 36 (H3K36me3) and is located deletion, to also trimethylate microtubules 40 (αTubK40me3) during mitosis, with αTubK40me3 required genomic stability. now show that monoallelic, Setd2-deficient cells...
Background Despite the remarkable success of immunotherapy in treating melanoma, understanding underlying mechanisms resistance remains limited. Emerging evidence suggests that upregulation tumor-specific major histocompatibility complex-II (tsMHC-II) serves as a predictive marker for response to anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) therapy various cancer types. The genetic and epigenetic pathways modulating tsMHC-II expression remain incompletely characterized....
Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there minimal evidence for effective therapies in the metastatic setting. Here, we present case of penile response Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due high expression carcinomas, including carcinoma. The patient had both radiographic and symptomatic improvement after two cycles treatment, despite having been treated multiple prior lines...
Significant strides have been made in the frontline treatment of patients with advanced clear cell renal carcinoma (ccRCC). There are multiple standard-of-care doublet regimens consisting either combined dual immune checkpoint inhibitors, ipilimumab and nivolumab, or combinations a vascular endothelial growth factor receptor tyrosine kinase inhibitor an inhibitor. Currently, there is emergence clinical trials examining triplet combinations. In COSMIC-313, randomized phase III trial for...
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated severity among melanoma, assessing outcomes of on active targeted or immune therapy. Methods Using the and Cancer Consortium (CCC19) registry, identified 307 diagnosed COVID-19. We used multivariable models assess demographic, cancer-related, treatment-related a...
The Cancer Genome Atlas undertook a comprehensive genetic analysis of chromophobe renal cell carcinoma, the first rare tumor types to be analyzed. This identified putative region origin as distal nephron. Alterations in mitochondrial function, mtDNA mutations, and recurrent structural rearrangements within TERT promoter were also identified.
10582 Background: IrAEs are prevalent in patients treated with immune checkpoint inhibitors (ICI) and mimic classical autoimmune diseases. IrAE risk prediction could improve clinical decision making patient safety for ICI-treated patients. Classical diseases show strong associations germline polymorphisms Human Leukocyte Antigen (HLA) variants, though it is unclear if these same genetic factors predispose to irAEs. To identify both tolerant irAE patients, we mined Vanderbilt University...
4529 Background: Adjuvant pembrolizumab significantly improved overall survival (OS) and is FDA-approved for adjuvant RCC treatment. However, there a paucity of data on sequential treatment following recurrence after or other immune-oncology (IO)-based therapies (PD-1 PD-L1 inhibitors) administered in the setting. Methods: This study included consecutive patients (pts) from 27 international centers who received IO-based systemic therapies. Safety efficacy subsequent therapy regimens that...
4549 Background: The standard of care for renal cell carcinoma (RCC) is physician-choice dual immunotherapy with ipilimumab/nivolumab (IO/IO) or a combination VEGF inhibitor (VEGF/IO). IMmotion 151 trial identified gene expression signatures that differentiate likelihood response to IO/IO (cluster 4 and 5 – T effector) versus VEGF/IO 1 2 - Angiogenic). Given the effector RNA-seq signature consists higher genes associated inflammation, we hypothesized patients phenotype would have rates...
<h3>Background</h3> Treatment of melanoma with immune checkpoint inhibitors (ICI) has dramatically changed outcomes.<sup>1</sup> Although ICI lack the traditional risks cytotoxic chemotherapy, up to 50% treated patients will experience an related adverse event (irAE).<sup>2</sup> Currently, we are unable predict which have irAE. Additionally, some develop more than one irAE, suggesting underlying predisposition. Autoantibodies, often associated development autoimmune diseases, could be a...
Abstract Background: Kidney cancer is estimated to affect 65,150 newly diagnosed individuals in 2013. Approximately 70% of these diagnoses will be clear cell renal carcinoma (ccRCC). Many targeted therapies for ccRCC are currently being pursued, as resistant radiation and often does not respond chemotherapy. The most commonly mutated tumor suppressor gene VHL, located on chromosome 3. loss 3p a high frequency event ccRCC, which also encompasses the genes PBRM1, BAP1, SETD2. Mutations one or...
Abstract Background: Kidney cancer is estimated to affect 65,150 newly diagnosed individuals in 2013. Approximately 70% of these diagnoses will be clear cell renal carcinoma (ccRCC). Many targeted therapies for ccRCC are currently being pursued, as resistant radiation and often does not respond chemotherapy. The most commonly mutated tumor suppressor gene VHL, located on chromosome 3. loss 3p a high frequency event ccRCC, which also encompasses the genes PBRM1, BAP1, SETD2. Mutations one or...
<p>fig legends for sup figures</p>
<p>fig legends for sup figures</p>